Duopharma Biotech expected to build on strong start

KUALA LUMPUR: Duopharma Biotech Bhd's prospects are expected to remain bright following a strong performance in the first quarter of 2023, as resilient patient footfall in the public and private hospital segments drove higher prescription pharmaceutical product sales.

In a company update, investment research firm RHB Research said Duopharma made a strong start to its financial year by booking a first quarter core profit of RM28.3mil, which made up 30% and 29% of its and consensus full-year expectations.